VKORC1 diplotype-derived dosing model to explain variability in warfarin dose requirements in Asian patients

Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 4, 2009, Pages 365-375

  Sandanaraj, Edwin ^a   Lal, Suman ^a   Cheung, Yin Bun ^b   Xiang, Xiaoqiang ^a   Kong, Ming Chai ^c   Lee, Lai Heng ^c   Ooi, London Lucien ^d   Chowbay, Balram ^a  

^a Humphrey Oei Institute of Cancer Research   (Singapore)

^b Clinical Trials and Epidemiology Research Unit   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Chinese; CYP2C19; CYP2C9; VKORC1 mRNA expression; Warfarin pharmacogenetics

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1 PROTEIN; WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; BODY WEIGHT; CHINESE; CONFERENCE PAPER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN TISSUE; LIVER LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; PHARMACOGENOMICS; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 70350433682     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.24.365     Document Type: Conference Paper

References (47)

1. Anand, S. S. and Yusuf, S.: Oral anticoagulant therapy in patients with coronary artery disease: a meta analysis. JAMA., 282(21): 2058-2067 (1999).
2. Smith, P., Arnesen, H. and Holme, I.: The effect of warfarin on mortality and reinfarction after myocardial infarction. N. Engl. J. Med., 323(3): 147-152 (1990).
3. Beyth, R. J., Milligan, P. E. and Gage, B. F.: Risk factors for bleeding in patients taking coumarins. Curr. Hematol. Rep., 1(1): 41-49 (2002).
4. Wells, P. S., Holbrook, A. M., Crowther, N. R. and Hirsh, J.: Interactions of warfarin with drugs and food. Ann. Int. Med., 121(9): 676-683 (1994).
5. Kamali, F., Khan, T. I. and King, B. P., Frearson, R., Kesteven, P., Wood, P., Daly, A. K. and Wynne, H.: Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin. Pharmacol. Ther., 75(3): 204-212 (2004).
6. Absher, R. K., Moore, M. E. and Parker, M. H.: Patient-specific factors predictive of warfarin dosage requirements. Ann. Pharmacother., 36(10): 1512-1517 (2002).
7. Gan, G. G., The, A., Goh, K. Y., Chong, H. T. and Pang, K. W.: Racial background is a determinant factor in the maintenance dosage of warfarin. Int. J. Hematol., 78(1): 84-86 (2003).
8. Scordo, M. G., Pengo, V., Spina, E., Dahl, M. L., Gusella, M. and Padrini, R.: Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther., 72(6): 702-710 (2002).
9. Breckenridge, A., Orme, M., Wesseling, H., Lewish, R. J. and Gibbsons, R.: Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin. Pharmacol. Ther., 15(4): 424-430 (1974).
10. Takahashi, H. and Echizen, H.: Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet., 40(8): 587-603 (2001).
11. O'Reilly, R. A.: Studies on the optical enantiomorphs of warfarin in man. Clin. Pharmacol. Ther., 16(2): 348-354 (1974).
12. Limdi, N. A. and Veenstra, D. L.: Warfarin pharmacogenetics. Pharmacotherapy., 28:1084-1097 (2008).
13. Lee, C. R., Goldstein, J. A. and Pieper, J. A.: Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics., 12(3): 251-263 (2002).
14. Taube, J., Halsall, D. and Baglin, T.: Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood., 96(5): 1816-1819 (2000).
15. Aithal, G. P., Day, C. P., Kwsteven, P. J. and Daly, A. K.: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet., 353(9154): 717-719 (1999).
16. Margaglione, M., Colaizzo, D., D'Andrea, G., Brancaccio, V., Ciampa, A., Grandone, E. and Di Minno, G.: Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost., 84(5): 775-778 (2000).
17. Scordo, M. G., Aklillu, E., Yasar, U., Dahl, M. L. and Spina, E.: Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a Black African population. Br. J. Clin. Pharmacol., 52(4): 447-450 (2001).
18. Yoon, Y. R., Shon, J. H., Kim, M. K., Lim, Y. C., Lee, H. R., Park, J. Y., Cha, I. J. and Shin, J. G.: Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br. J. Clin. Pharmacol., 51(3): 277-280 (2001).
19. Zhao, F., Loke, C., Rankin, S. C., Guo, J. Y., Lee, H. S., Wu, T. S., Tan, T., Liu, T. C., Lu,W. L., Lim, Y. T., Zhang, Q., Goh, B. C. and Lee, S. C.: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther., 76(3): 210-219 (2004).
20. Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L. and Rettie, A. E.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med., 352(22): 2285-2293 (2005).
21. Li, T., Chang, C. Y., Jin, D. Y., Lin, P. J., Khvorova, A. and Stafford, D. W.: Identification of the gene for vitamin K epoxide reductase. Nature., 427(6974): 541-544 (2004).
22. Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hörtnagel, K., Pelz, H. J., Lappegard, K., Seifried, E., Scharrer, I., Tuddenham, E. G., M7uller, C. R., Strom, T. M. and Oldenburg, J.: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature., 427(6974): 537-541 (2004).
23. D'Andrea, G., D'Ambrosio, R. L., Di Perna, P., Chetta, M., Santacroce, R., Brancaccio, V., Grandone, E. and Margaglione, M.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood., 105(2): 645-649 (2005).
24. Yuan, H. Y., Chen, J. J., Lee, M. T., Wung, J. C., Chen, Y. F., Charng, M. J., Lu, M. J., Hung, C. R., Wei, C. Y., Chen, C. H., Wu, J. Y. and Chen, Y. T.: A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet., 14(13): 1745-1751 (2005).
25. Wadelius, M., Chen, L.Y., Downes, K., Ghori, J., Hunt, S., Eriksson, N., Wallerman, O., Melhus, H., Wadelius, C., Bentley, D. and Deloukas, P.: Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J., 5(4): 262-270 (2005).
26. Klein, T. E., Altman, R. B. and Eriksson, N., et al.: Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med., 360: 753-764 (2009).
27. Lal, S., Sandanaraj, E., Jada, S. R., Kong,M. C., Lee, L. H., Goh, B. C., Lee, S. C. and Chowbay, B.: Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients. Br. J. Clin. Pharmacol., 65(2): 260-264 (2008).
28. Banfield, C. and Rowland, M.: Stereospecific fluorescence high-performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine. J. Pharm. Sci., 73(10): 1392-1396 (1984).
29. Montgomery, D. C., Peck, E. A. and Vining, G. G.: Validation of regression models. In Introduction to Linear Regression Analysis (3rd ed.). New York, Wiley publishers, USA, 2001.
30. Lal, S., Jada, S. R., Xiang, X., Lim, W. T., Lee, J. D. and Chowbay, B.: Pharmacogenetic of target genes across the warfarin pharmacological pathway. Clin. Pharmacokinet., 45(12): 1189-1200 (2006).
31. Lee, S. C., Ng, S. S., Oldenburg, J., Chong, P. Y., Rost, S., Guo, J. Y., Yap, H. L., Rankin, S. C., Khor, H. B., Yeo, T. C., Ng, K. S., Soong, R. and Goh, B. C.: Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin. Pharmacol. Ther., 79(3): 197-205 (2006).
32. Mushiroda, T., Ohnishi, Y., Saito, S., Takahashi, A., Kikuchi, Y., Saito, S., Shimomura, H., Wanibuchi, Y., Suzuki, T., Kamatani, N. and Nakamura, Y.: Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J. Hum. Genet., 51(3): 249-253 (2006).
33. Veenstra, D. L., You, J. H., Rieder, M. J., Farin, F. M., Wilkerson, H. W., Blough, D. K., Cheng, G. and Rettie, A. E.: Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics., 15(10): 687-691 (2005).
34. Marsh, S., King, C.R., Porche-Sorbet, R.M., Scott-Horton, T. J. and Eby, C. S.: Population variation in VKORC1 haplotype structure. J. Thromb. Haemost., 4(2): 473-474 (2006).
35. Chenhsu, R. Y., Chiang, S. C., Chou, M. H. and Lin,M. F.: Longterm treatment with warfarin in Chinese population. Ann. Pharmacother., 34(12): 1395-1401 (2000).
36. Yu, H. C., Chan, T. Y., Critchely, J. A. and Woo, K. S.: Factors determining the maintenance dose of warfarin in Chinese patients. Q. J. Med., 89(2): 127-135 (1996).
37. Zhu, Y., Shennan, M., Reynolds, K. K., Johnson, N. A., Herrnberger, M. R., Valdes, R-Jr. and Linder, M. W.: Estimation of warfarin dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin. Chemistry., 53(7): 1199-1205 (2007).
38. Kimura, R., Miyashita, K., Kokubo, Y., Akaiwa, Y., Otsubo, R., Nagatsuka, K., Otsuki, T., Okayama, A., Minematsu, K., Naritomi, H., Honda, S., Tomoike, H. and Miyata, T.: Genotypes of vitamin K epoxide reductase, gamma glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb. Res., 120(2): 181-186 (2007).
39. Aquilante, C. L., Langaee, T. Y., Lopez, L. M., Yarandi, H. N., Tromberg, J. S., Mohuczy, D., Gaston, K. L., Waddell, C.D., Chirico, M. J. and Johnson, J. A.: Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther., 79(4): 291-302 (2006).
40. George, S. Z., Wallace, M. R., Wright, T. W., Moser, M. W., Greenfield, W. H-3rd., Sack, B. K., Herbstman, D. M. and Fillingim, R. B.: Evidence for a biopsychosocial influence on shoulder pain: Pain catastrophiizing and catechol-O-methyltransferase (COMT) diplotype predict clinical pain ratings. Pain., 136(1-2): 53-61 (2008).
41. Sandanaraj, E., Jada, S. R., Shu, X., Lim, R., Lee, S. C., Zhou,Q., Zhou, S., Goh, B. C. and Chowbay, B.: Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients. Pharmacogenomics J., 8(3): 174-185 (2008).
42. Ho, R. H., Choi, L., Lee, W., Mayo, G., Schwarz, U. I., Tirona, R. G., Bailey, D. G., Michael Stein, C. and Kim, R. B.: Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet. Genomics., 17(8): 647-656 (2007).
43. Tham, L. S., Goh, B. C., Nafziger, A., Guo, J. Y., Wang, L. Z., Soong, R. and Lee, S. C.: A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in Vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin. Pharmacol. Ther., 80(4): 346-355 (2006).
44. Shepherd, A.M., Hewick, D. S., Moreland, T. A. and Stevenson, I. H.: Age as a determinant of sensitivity to warfarin. Br. J. Clin. Pharmacol., 4(3): 315-320 (1977).
45. Hamberg, A. K., Dahl, M. L., Barban, M., Scordo, M. G., Wadelius, M., Pengo, V., Padrini, R. and Jonsson, E. N.: A PK-PD model for predicting the impact of Age, CYP2C9 and VKORC1 genotype on individualization of warfarin therapy. Clin. Pharmacol. Ther., 81(4): 529-538 (2007).
46. Loebstein, R., Yonath, H., Peleg, D., Almog, S., Rotenberg, M., Lubetsky, A., Roitelman, J., Harats, D., Halkin, H. and Ezra, D.: Interindividual variability in sensitivity to warfarin-Nature or nurture? Clin. Pharmacol. Ther., 70(2): 159-164 (2001).
47. You, J. H., Zuo, Z., Lo, C. M., Zhou, L., Yiu, H. H., Chau, C. T., Choi, K. C., Choi, D. K., Wong, R. S. and Cheng, G.: Any effect of CYP2C9 variants on warfarin clearance in Chinese patients? Thromb. Haemost., 97(5): 866-868 (2007).